Released : February 21, 2020 07:00 RNS Number : 6770D MaxCyte, Inc. 21 February 2020 NOT FOR DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL.
Released : February 20, 2020 18:18 RNS Number : 6728D MaxCyte, Inc. 20 February 2020 SCHEDULE 6 AIM BLOCK ADMISSION RETURN / TOTAL VOTING RIGHTS Please ensure the entries on this return are typed a. Name of company MaxCyte, Inc. b. Name of scheme(s) MaxCyte Long Term Incentive Plan
Released : February 05, 2020 07:00 RNS Number : 9797B MaxCyte, Inc. 05 February 2020 FOR IMMEDIATE RELEASE MaxCyte's CEO to Present Update on Life Sciences Business & First-in-class CARMA™ Cellular Therapies at BIO CEO & Investor Conference in New York Gaithersburg, Maryland - 5
Released : January 24, 2020 16:31 RNS Number : 9167A MaxCyte, Inc. 24 January 2020 MaxCyte, Inc. ("MaxCyte" or the "Company") Grant of Options Gaithersburg, Maryland - 24 January 2020 : MaxCyte (LSE: MXCT, MXCS), the global clinical-stage cell-based therapies and life sciences
Released : January 22, 2020 17:15 RNS Number : 6475A MaxCyte, Inc. 22 January 2020 TR-1: S tandard form for notification of major holdings NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible) i 1a.
Released : January 22, 2020 17:11 RNS Number : 6469A MaxCyte, Inc. 22 January 2020 TR-1: S tandard form for notification of major holdings NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible) i 1a.
Released : January 22, 2020 17:08 RNS Number : 6465A MaxCyte, Inc. 22 January 2020 TR-1: S tandard form for notification of major holdings NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible) i 1a.
Released : January 20, 2020 07:00 RNS Number : 2421A MaxCyte, Inc. 20 January 2020 MaxCyte, Inc. ("MaxCyte" or the "Company") Trading Update · Revenue exceeds market expectations · Five new gene-editing cell therapy deals signed in 2019; eight clinical and commercial cell
Released : December 19, 2019 07:00 RNS Number : 4058X MaxCyte, Inc. 19 December 2019 MaxCyte Appoints New Executive Vice President, Business Development for CARMA™ Cellular Therapies and Trial Update - Shruti Abbato will lead development of new partnerships for the Company's
Released : December 16, 2019 17:25 RNS Number : 0553X MaxCyte, Inc. 16 December 2019 MaxCyte, Inc. ("MaxCyte" or the "Company") Director/PCA transaction initial notification Gaithersburg, Maryland - 16 December 2019: MaxCyte (LSE: MXCT, MXCS), the global cell-based therapies and life
